chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Dizziness, Fatigue, Mental fatigue
Clinical narrative: Aches; chills; fever; fatigue; diarrhea; dizzy; mental fog; Injection site pain; Injection site swelling; arm rash; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Mar2021 at 13:00 (at the age of 45-year-old) and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 13:00 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, ulcerative colitis, ADD (attention deficit disorder) and sickle cell trait. The patient was allergic to adhesive and latex. Concomitant medications included paracetamol (TYLENOL ARTHRITIS). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Mar2021 at 13:45 the patient experienced aches, chills, fever, fatigue, diarrhea, dizzy, mental fog, injection site pain, injection site swelling and arm rash. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events aches, chills, fever, fatigue, diarrhea, dizzy, mental fog, injection site pain, injection site swelling and arm rash were recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Rash, Vaccination site pain, Vaccination site swelling
Clinical narrative: Aches; chills; fever; fatigue; diarrhea; dizzy; mental fog; Injection site pain; Injection site swelling; arm rash; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Mar2021 at 13:00 (at the age of 45-year-old) and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 13:00 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, ulcerative colitis, ADD (attention deficit disorder) and sickle cell trait. The patient was allergic to adhesive and latex. Concomitant medications included paracetamol (TYLENOL ARTHRITIS). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Mar2021 at 13:45 the patient experienced aches, chills, fever, fatigue, diarrhea, dizzy, mental fog, injection site pain, injection site swelling and arm rash. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events aches, chills, fever, fatigue, diarrhea, dizzy, mental fog, injection site pain, injection site swelling and arm rash were recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Alopecia
Clinical narrative: Significant hair loss; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 05Mar2021 at 16:15 (at the age of 49-years-old) and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 31Mar2021 (at the age of 49-years-old), as a single dose for COVID-19 immunization. Medical history included autoimmune disease. The patient did not receive any medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 16Mar2021, the patient experienced significant hair loss. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the event significant hair loss was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: Tingling/numbness in left hand and some tingling in left arm; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 06Apr2021 at 14:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medication included cetirizine hydrochloride (ZYRTEC). The patient had no allergic to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 14:45, the patient experienced tingling or numbness in the left hand and left arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event tingling or numbness in the left hand and left arm was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia, Tendonitis
Clinical narrative: I am still having muscle and joint pain.; I am still having muscle and joint pain.; Hips shoulder Achilles arms; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Feb2021 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had previously taken Phenergan, and experienced drug allergy. Any other medication taken within two weeks of vaccination was not reported. Prior to vaccination, the patient was not diagnosed with COVID -19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Feb2021 the patient was still having muscle and joint pain, hips shoulder Achilles arms. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the events still having muscle and joint pain, hips shoulder Achilles arms was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Very itchy; This is a spontaneous report from a non-contactable consumer. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration on 01Apr2021 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On an unspecified date in Apr2021, the patient was very itchy for several days following the vaccine. The event did not result in a doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the event which included treatment with CLARITEN. It was reported that the issue improved over time and after taking CLARITEN. The clinical outcome of the event was very itchy was resolved on an unspecified date in Apr2021.  No follow-up attempts are possible; information about lot number cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: Headache, Pain, Pyrexia, Vaccination site pain
Clinical narrative: Aches; Soreness around shot; Fever; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A male patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 05Apr2021 at 14:15 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 15Mar2021 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 06Apr2021, the patient experienced soreness around shot (vaccination site pain), fever, aches and headache. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of soreness around shot (vaccination site pain), fever, aches and headache were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: Paresthesia in bilateral legs 3 days after vaccination; This is a spontaneous report from a contactable physician. A 59-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via intramuscular route of administration on 18Mar2021 (at the age of 59-years-old), as a single dose for COVID-19 immunisation. Medical history included anemia, seasonal allergy and sulfonamide allergy. Concomitant medications were not provided. The patient previously took macrobid on unknown date for an unspecified indication and experienced drug allergy. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021, 3 days after vaccination, the patient experienced paresthesia in bilateral legs. The event resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the event. The clinical outcome of the event paresthesia in bilateral legs was recovered with sequelae on an unknown date in 2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: Menstruation started March 11 and lasted until March 29th and Period started again on April 6; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Mar2021 at 10:45 (at the age of 40-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27Mar2021 (at the age of 40-years-old); both as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Concomitant medications included unspecified birth control medication from unknown date. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Mar2021, the patient's menstruation started and lasted till  29Mar2021. On 06Apr2021, the period started again. The patient had very regular periods because of birth control and these weird periods only started after the vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event menstruation started on 11Mar2021 and lasted till 29Mar2021 and period started again on 06Apr2021 (menstruation irregularity) was not recovered at the time of report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Painful lymph node on left collar bone; Swollen lymph node on left collarbone; This is a spontaneous report from a contactable other healthcare professional, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 26Mar2021 at 09:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfa (sulfonamide) allergy. The patient did not receive any medication within two weeks of the COVID-19 vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 01Apr2021 at 09:00, approximately 6 days after the first dose, the patient experienced a very painful and swollen lymph node on left collarbone. The event did not result in a doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event very painful and swollen lymph node on left collarbone was resolving at the time of this report.  No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Burning sensation, Myalgia
Clinical narrative: arm burning; pain joint; muscle pain; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: er8730) via an unspecified route of administration in the left arm on 29Mar2021 at 17:00 (at the age of 73-year-old) as a single dose for COVID-19 immunisation. Medical history included coronary artery disease (CAD) since unknown date and heart bypass on an unknown date. The patient reported an allergy to flagyl and sensitivity to blood thinners. Concomitant medications included losartan (MANUFACTURER UNKNOWN) and carvedilol (MANUFACTURER UNKNOWN), all received within two weeks of vaccination for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021, 8 days later, the patient experienced arm burning, pain joint and muscle pain. The patient did not receive any treatment for the events. The clinical outcome of the events arm burning, pain joint and muscle pain was recovered with sequelae on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Pyrexia, Vaccination site pain
Clinical narrative: slight fever; injection site arm pain; felt 'woozy' (Dizziness); This is a spontaneous report from a non-contactable pharmacist. A 38-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 06Apr2021 at 13:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as unknown. It was unknown whether the patient had any allergies to any medications, food, or other products. It was unknown if the patient received any other medications within two weeks of vaccination and also unknown, if the patient received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 06Apr2021, after the vaccination, the patient felt woozy (Dizziness). A couple of hours later, at 15:00 on 06Apr2021, the patient had a slight fever and injection site arm pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events felt woozy (Dizziness), slight fever, and injection site arm pain were recovered a few hours later on 06Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Product preparation issue
Clinical narrative: incorrectly diluted the vaccine; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EW0153,) via an unspecified route of administration, in the left arm on 06Apr2021 at 11:15 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included testosterone (MANUFACTURER UNKNOWN), and buspirone (MANUFRATURER UNKNOWN) both were from unknown dates and for unspecified indications.  Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 06Apr2021 at 11:15, Walgreen's (the facility name where the vaccine administered) called and said that they incorrectly diluted the vaccine and did not shared any information as what to do. The patient asked for advice on what to do. The event did not result in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the event. The clinical outcome of the event incorrectly diluted the vaccine was not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Rash erythematous, Urticaria
Clinical narrative: Red rash appeared on left arm below where the shot was adminstered four days after getting shot; welts appeared on left arm below where the shot was adminstered four days after getting shot; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 02Apr2021 at 13:15 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included goiter-Thyroid. The patient had no known allergies. Concomitant medications included cimicifuga racemosa (BLACK COHOSH) 540mg, cyanocobalamin (VITAMIN B12) 1000mcg, and colecalciferol (VITAMIN D3) 25mcg from an unknown date for an unspecified indication. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 12Mar2021 at 13:15 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 08:00 the patient experienced red rash and welts appeared on left arm below where the shot was administered. Four days after getting shot. Patient did not receive treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events red rash, welts was not recovered at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: chronic pain in both of the shoulder joints; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received his first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 13Mar2021 at 07:00 (at the age of 56-years-old) as a single dose and his second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734,) via an unspecified route of administration in the right arm on 05Apr2021 at 09:45 (at the age of 56-years-old) as single dose for COVID-19 immunisation. Medical history was not reported. The patient had a history of allergy to sweet potatoes. Concomitant medications included venlafaxine hydrochloride (EFFEXOR), amfetamine aspartate (ADDERALL), amlodipine besilate (AML), multivitamins and gemfibrozil (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Mar2021 at 15:00 the patient had experienced chronic pain in both of the shoulder joints which was not severe, but uncomfortable. The patient did not receive any treatment for the reported event. The clinical outcome of the event chronic pain in both of the shoulder joints was not resolved at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Menstrual disorder
Clinical narrative: Menstrual period started a week early.; This is a spontaneous report from a non-contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EdD7533) via an unspecified route of administration in the left arm on 27Mar2021 at 09:30 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not receive any medication within two weeks of vaccination. The patient did not have allergies to medications, food, or other products The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206 via an unspecified route of administration in the left arm on 06Mar2021 at 10:15 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 10:00 the patient experienced menstrual period that started a week early. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported adverse event. The clinical outcome of the event menstrual period started a week early was unknown at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Skin mass, Vaccination site rash
Clinical narrative: Redness at injection site; lump under the skin; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 03Apr2021 at 14:00 (at the age of 74-year-old) as a single dose for COVID-19 immunisation. Medical history included hyperlipidaemia, hypothyroidism, osteoporosis, arthritis and seasonal allergy. Concomitant medications included rosuvastatin (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN) and duloxetine (MANUFACTURER UNKNOWN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 06Mar2021 at 14:00 (at the age of 74-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 12:00, the patient experienced redness at injection site and lump under the skin. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events redness at injection site and lump under the skin was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache
Clinical narrative: Headache; Fatigue; Chills; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 05Apr2021(at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included anemia, neuralgia trigeminal and penicillin allergy. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 19:30 hours the patient experienced headache, fatigue, chills. The patient did not receive any treatment for the event. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, fatigue and chills was recovering.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: menstrual cycle began 10 days after previous cycle; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0151) via an unspecified route of administration in the arm left on 03Apr2021 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not receive any medication within two weeks of vaccination. The patient previously took the first dose of BNT162b2 (BIONTECH COVID-19 mRNA VACCINE; lot number: UNKNOWN) via an unspecified route of administration on 26Feb2021 (at the age of 42-year-old) as a single dose for covid-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Apr2021 the patient experienced a menstrual cycle that began 10 days after the previous cycle. She was always had 28 days cycle and this cycle began at 10 days. The patient did not receive any treatment for the event. The clinical outcome of the event menstrual cycle began 10 days after the previous cycle was not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: U
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: Experienced some numbness; Tingling in left leg; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old patient of an unknown gender received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150), via an unspecified route of administration in the right arm on 06Apr2021 at 08:15 (at the age of 33-year-old), as a single dose for COVID-19 immunisation. Medical history included asthma. The patient was allergic to nuts and eggs. Concomitant medications included albuterol sulfate (MANUFACTURER UNKNOWN) since an unknown date for an unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 11:15, the patient experienced some numbness and tingling in left leg. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events numbness and tingling in left leg was not resolved.  No further information is expected; information about lot number cannot be obtained.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Swelling
Clinical narrative: Lump size of a pea on collarbone; Pain if touched; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 30Mar2021 at 05:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and bronchitis. The patient had no allergies to medications, food, or other products. Concomitant medications included cyanocobalamin (VITAMIN B12), women's multivitamin (MANUFACTURER UNKNOWN) and birth control (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 17:00, 6 days after the shot, the patient experienced lump size of a pea on collarbone and caused pain if touched. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events lump size of a pea on collarbone and pain if touched was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia, Pain, Pain in extremity
Clinical narrative: Joint pain in my shoulder and upper arm; Joint pain in my shoulder and upperarm; Joint pain in my shoulder and upperarm making it difficult to raise my armto put my arm in the sleeve of a t-shirt.Any movement out to the side ispainful.; Burning sensation when press along the deltoid muscle; This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the arm left on 30Mar2021 at 11:30 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high. Concomitant medications included hydrochlorothiazide (MANUFACTURER UNKNOWN) for unknown indication from an unknown date. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 04Apr2021, the patient experienced joint pain in shoulder and upper arm making it difficult to raise arm to put the arm in the sleeve of a T-shirt. Any movement out to the side was painful. The patient experienced burning sensation when press along the deltoid muscle. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events pain in joint involving the shoulder region, pain in arm, pain upon movement and muscle burning sensation were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Oral herpes, Thirst, Throat irritation
Clinical narrative: soreness at injection site; Joint pain; headache; excessive thirst; cold sores all over lips; scratchy throat; mild post nasal drip; This is a spontaneous report from a contactable other healthcare professional, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Apr2021 at 10:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included mild congenital pulmonary stenosis, chronic dry eye syndrome, and other food allergies all from an unknown duration. The patient previously took erythromycin (MANUFACTURER UNKNOWN), BACTRIM and doxycycline (MANUFACTURER UNKNOWN) all from an unknown date for an unknown indication and experienced allergy to these drugs. Concomitant medications included ethinylestradiol; segesterone acetate (ANNOVERA), calcium citrate; magnesium citrate (MAG CITRATE), ascorbic acid (VITAMIN C), curcuma longa (TURMERIC), and docosahexaenoic acid (DHA), vitamin B (MANUFACTURER UNKNOWN) and vitamin D (MANUFACTURER UNKNOWN); all taken for an unknown indication and received within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 03Apr2021, the patient experienced joint pain, headache, excessive thirst, cold sores all over lips, scratchy throat, and mild post nasal drip all these symptoms lasting through the fourth day and also experienced soreness at injection site which was mild and last two days. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events joint pain, headache, excessive thirst, cold sores all over lips, scratchy throat, and mild post nasal drip was not recovered at the time of this report and that of soreness at injection site which was mild was recovered on 05Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Upper-airway cough syndrome, Vaccination site pain
Clinical narrative: soreness at injection site; Joint pain; headache; excessive thirst; cold sores all over lips; scratchy throat; mild post nasal drip; This is a spontaneous report from a contactable other healthcare professional, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Apr2021 at 10:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included mild congenital pulmonary stenosis, chronic dry eye syndrome, and other food allergies all from an unknown duration. The patient previously took erythromycin (MANUFACTURER UNKNOWN), BACTRIM and doxycycline (MANUFACTURER UNKNOWN) all from an unknown date for an unknown indication and experienced allergy to these drugs. Concomitant medications included ethinylestradiol; segesterone acetate (ANNOVERA), calcium citrate; magnesium citrate (MAG CITRATE), ascorbic acid (VITAMIN C), curcuma longa (TURMERIC), and docosahexaenoic acid (DHA), vitamin B (MANUFACTURER UNKNOWN) and vitamin D (MANUFACTURER UNKNOWN); all taken for an unknown indication and received within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 03Apr2021, the patient experienced joint pain, headache, excessive thirst, cold sores all over lips, scratchy throat, and mild post nasal drip all these symptoms lasting through the fourth day and also experienced soreness at injection site which was mild and last two days. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events joint pain, headache, excessive thirst, cold sores all over lips, scratchy throat, and mild post nasal drip was not recovered at the time of this report and that of soreness at injection site which was mild was recovered on 05Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Pain, Pyrexia
Clinical narrative: spacey feeling out of it; moderate to severe body aches; Fatigue; low fever; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8737) via an unspecified route of administration in the left arm on 05Apr2021 at 12:00 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19, thyroid cancer and blood clotting disorder. Concomitant medications were not reported. The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 15:00, the patient experienced fatigue, moderate to severe body aches, low fever and spacey feeling out of it(spaced out). The patient did not receive any treatment for the reported events. The clinical outcome of the events fatigue, moderate to severe body aches, low fever and spacey feeling out of it was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary mass
Clinical narrative: Hard painful lump in left armpit; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 04Mar2021 at 09:00 (at the age of 37-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 24Mar2021 at 14:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. It was unknown if patient had any allergies to medications, food, or other products. Concomitant medications included unspecified hair, skin and nails vitamins (MANUFACTURER UNKNOWN) for an unknown indication and from an unknown start date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 06Mar2021 at 03:00, the patient experienced hard painful lump in left armpit. The patient stated that she developed a hard painful lump in left armpit a few days after getting the first shot which was about the size of an egg. After getting acupuncture, lump went down and after the second shot it came back, but was not as painful and went away on its own. Therapeutic measure was taken as a result of adverse event and included treatment with acupuncture. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event hard painful lump in left armpit was resolved on an unspecified date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Pharyngeal swelling, Vaccination site pain
Clinical narrative: Dizziness; throat swelling; headache; Injection site pain; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history included pollen allergy, allergy to molds and grass allergy. Concomitant medications included cetirizine hydrochloride (ZYRTEC), sertraline (MANUFACTURER UNKNOWN) 50mg, and drospirenone, ethinylestradiol (LORYNA) 3mg/0.2mg all taken from unknown date, for unspecified indication. The patient was allergic to various pollens, molds and grasses. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 the patient experienced dizziness for the first few minutes, throat swelling in the hour after receiving the vaccine but no loss of breathing. The  patient experienced headache for 2 days, immediate pain at injection site that increased but it went away over 48 hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care The patient did not receive any treatment for the reported adverse events. The clinical outcome of the event dizziness was recovered on 01Apr2021. The clinical outcome of the event of headache was recovered 03Apr2021 after the duration of 2 days. The clinical outcome of the event injection site pain was recovered on 03Apr2021 after the duration of 48 hours. While the clinical outcome of the event of throat swelling was recovered on unspecified date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Oropharyngeal pain
Clinical narrative: SORE THROAT; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27Mar2021 at 09:15 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. Medical history included RT hip replacement and heart surgery. Patient reported unspecified allergies to food, medications and other products. Patient received unspecified medications within 2 weeks of vaccination. Prior to the vaccination, it was unknown if the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 05Apr2021, the patient experienced sore throat. The patient did not receive any treatment for the event. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event sore throat was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Ear infection, Fatigue, Headache, Pain
Clinical narrative: Headache; fever; chills; fatigue; vomiting; ear infection; Achy; This is a spontaneous report from a contactable healthcare professional, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: er8734) via an unspecified route of administration in the arm left on an unknown date in Apr2021(at the age of 49-year-old) at 09:15 as a single dose for COVID-19 immunisation. Medical history included migraine, arthritis and COVID-19. Concomitant medications included mometasone furoate (FLONASE), topiramate (TOPAMAX), azelastine (MANUFACTURER UNKNOWN), ibuprofen (MANUFACTURER UNKNOWN) and magnesium (MANUFACTURER UNKNOWN)all from an unknown date for unknown indication. The patient previously took Ceftin and experienced drug allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 at 2.30 patient experienced Covid Arm + 5 days, Headache 2 days (48 hours after), Achy, fever, chills, fatigue, vomiting and ear infection post vaccine 3 days. Therapeutic measures were taken as a result of ear infection which included treatment with ear drop for Otitis media/externa. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events Covid Arm, Headache 2 days, Achy, fever, chills, fatigue, vomiting and ear infection were resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.